<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281099</url>
  </required_header>
  <id_info>
    <org_study_id>240</org_study_id>
    <nct_id>NCT00281099</nct_id>
  </id_info>
  <brief_title>Managed Ventricular Pacing (&quot;MVP&quot;) Trial</brief_title>
  <acronym>MVP</acronym>
  <official_title>MVP Trial (Managed Ventricular Pacing (&quot;MVP&quot;) Versus Backup Ventricular Pacing at a Rate of 40 Beats Per Minute (&quot;VVI 40&quot;) Pacing Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare two device settings (sets of instructions) used by the
      ICD. The Implantable Cardiac Defibrillator (&quot;ICD&quot;) can be set to use one wire (top or bottom
      of the heart) or two wires (top and bottom). The study will compare how much time either ICD
      wire is used by the ICD and the status of congestive heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent research supports the hypothesis that reducing the amount of pacing in the lower right
      chamber of the heart may prevent the progression of congestive heart failure (CHF) in some
      implantable cardioverter defibrillator (ICD) patients. CHF refers to symptoms (shortness of
      breath, fatigue, fluid overload) caused by decreased pumping action of the heart muscle. The
      ICD can be set to use one wire (top or bottom of the heart) or two wires (top and bottom).
      Both settings allow the heart to beat more naturally using its own electrical signals. Two
      device settings will be compared. Managed ventricular pacing (MVP) will allow the ICD to use
      both wires only as necessary. This setting allows the ICD to send electrical signals to the
      top and bottom chambers of the heart if needed. The other setting, ventricular pacing (VVI)
      will allow the ICD to operate the bottom chamber of the heart if it is needed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to reach statistical significance toward primary endpoint
  </why_stopped>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality and Heart Failure-related Urgent Care Visits and Heart Failure (&quot;HF&quot;) Hospitalizations.</measure>
    <time_frame>Enrollment to last visit (up to 45 months post-randomization) or death</time_frame>
    <description>A composite endpoint of all cause mortality and HF hospitalizations or urgent care. (Emergency Department, Urgent Clinic visits, or hospitalizations wiht intravenous medications for HF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Worsening Heart Failure-related Adverse Events</measure>
    <time_frame>Enrollment to last visit (up to 45 months post-randomization)</time_frame>
    <description>HF event meeting primary endpoint definition, or adverse events associated with, but not limited to, any of the following: symptoms or physical signs compatible with worsening HF, laboratory evidence of HF, any modification of oral heart failure therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Patients by NYHA (New York Heart Association) Functional Class Over Time</measure>
    <time_frame>Baseline, 12, 24 and 36 month visits</time_frame>
    <description>NYHA Classification at each scheduled Follow-up visit. The scale for this measure is as follows: NYHA I= best, NYHA IV= worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Chamber Dimensions and Wall Thicknesses</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) Ejection Fraction and Fractional Shortening</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Ejection Fraction is the percentage of a patient's blood moved out of the left venricle when the heart pumps. The measure is recorded as a percentage(0-100%) and the normal range is 50-85%.
LV Fractional Shortening is the percent change in a patient's LV internal dimensions between systole (when the ventricles contract and expel blood) and diastole (when the ventricles expand and receive blood). The measure is recorded as a percentage(0-100%) and the normal range is 30-45%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) and Left Atrial (LA) Volumes</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular (LV) Sphericity Index</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Sphericity Index is a ratio of LV long axis dimension to the LV short axis dimension. Healthy hearts have an elliptical LV cross-sectional shape. A value of 1 denotes a circular or more globular shape, while larger values denote healthier hearts with more elliptical cross sections. Literature has shown that when the ratio used is short axis/long axis, normal hearts have a median LV sphericity index of 0.56, with a range of (0.51-0.60). This translates to median=1.79,range=(1.67,1.96) for long/short axis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Velocity Measures</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Deceleration Time</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Atrial (LA) and Mitral Regurgitation (MR) Areas</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Mitral Regurgitation (MR) Severity Score</measure>
    <time_frame>Baseline, 12, and 24 month visits</time_frame>
    <description>Echocardiogram measures for this endpoint were obtained at multiple time points. Composite MR Severity was measured on a scale of &quot;None to Trivial&quot; to &quot;Grade IV&quot;, with Grade IV being the worst possible score and &quot;None to Trivial&quot; being the best possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Ventricular Tachycardia (&quot;VT&quot;) and Ventricular Fibrillation (&quot;VF&quot;) Episodes</measure>
    <time_frame>Enrollment to last collection of data from the implanted ICD (up to 45 months post-randomization)</time_frame>
    <description>Annualized Rates of Days of True VT/VF and Inappropriately detected non-VT/VF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clinically Important or Persistent Atrial Tachycardia or Atrial Fibrillation (AT/AF) in Subjects With no Prior AF History</measure>
    <time_frame>Enrollment to last collection of data from the implanted ICD (up to 45 months post-randomization)</time_frame>
    <description>Persistent AF was defined as any of the following:
2 consecutive visits in which the patient presents with AF
7 consecutive days of at least 22 hours per day of AT/AF
A cardioversion prior to 7 consecutive days of at least 22 hours per day of AT/AF
Clinically Important AF was defined as more than 20 hours of AT/AF in a single day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of a Pacing Indication During the Study</measure>
    <time_frame>Enrollment to last visit (up to 45 months post-randomization)</time_frame>
    <description>Physician identification of a Class I Pacing Indication. A Class I Pacing Indication implies that the benefit of pacing the heart far exceeds the risk, and that the procedure to implant the pacing device should be performed. For this indication there is general agreement that pacing the heart is beneficial, useful, and effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Usage Affecting Heart Rate and Atrioventricular (&quot;AV&quot;) Conduction</measure>
    <time_frame>Enrollment, 6 Months, 12 Months, 24 Months, 30 Months, 36 Months</time_frame>
    <description>Whether a subject is on each of a pre-specified set of drugs or classes of drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Ventricular Pacing</measure>
    <time_frame>Enrollment, 6, 12, 24 and 36 month visits</time_frame>
    <description>The percentage of a patients' ventricular beats that were paced by the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (&quot;QOL&quot;) Score</measure>
    <time_frame>Baseline, 12, 24, and 36 month visits</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire (&quot;MLWHFQ&quot;) and Kansas City Cardiomyopathy Questionnaire (&quot;KCCQ&quot;) Quality of Life(&quot;QOL&quot;) Scores. For KCCQ, positive values mean improved QOL compared to baseline. For MLWHFQ, negative values mean improved QOL compared to baseline.
Scales: KCCQ 0-100 (0=worst, 100 best); MLWHFQ 0-105 (105=worst, 0=best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Enrollment to last visit (up to 45 months post-randomization) or death</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD-indicated Patients With Class I Pacemaker Indication.</measure>
    <time_frame>Period of time prior to patient consent when considering patient for Implant/Enrollment</time_frame>
    <description>Number of subjects screened prior to enrollment that had Class I pacing indication at time of implant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1031</enrollment>
  <condition>Heart Disease</condition>
  <arm_group>
    <arm_group_label>VVI 40 pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Backup ventricular pacing (VVI) at 40 beats per minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVP pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Managed ventricular pacing (MVP) at 60 beats per minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD (Implantable Cardioverter Defibrillator)</intervention_name>
    <description>VVI 40 vs. MVP</description>
    <arm_group_label>VVI 40 pacing</arm_group_label>
    <arm_group_label>MVP pacing</arm_group_label>
    <other_name>Intrinsic™</other_name>
    <other_name>EnTrust™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Conventional indication for ICD therapy according to current evidence-based guidelines
             and in accordance with the corresponding United States Centers for Medicare and
             Medicaid Services National Coverage Determination for the use of ICDs.

          -  Prior myocardial infarction (&quot;MI&quot;) and an left ventricular ejection fraction (&quot;LVEF&quot;)
             of less than 30%

          -  Ischemic Dilated Cardiomyopathy (IDCM), New York Heart Association (&quot;NYHA&quot;) Class II
             or II heart failure, and LVEF less than or equal to 35%

          -  Non-Ischemic Dilated Cardiomyopathy (NIDCM) greater than 3 months, NYHA Class II or II
             heart failure, and LVEF less than or equal to 35%

          -  First ICD implant

          -  Successful implant with a study device with approved labeling

        Exclusion Criteria:

          -  Failure to meet any of the inclusion criteria

          -  Class I pacing indication

          -  Chronic atrial fibrillation (&quot;AF&quot;) without any documented sinus mechanism for at least
             6 months

          -  Inability or unwillingness to give informed consent

          -  Life expectancy less than 12 months or a heart transplant anticipated within 6 months

          -  Inability to successfully comply with study participation and follow up requirements

          -  Patient involved in another clinical trial that may confound the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael O Sweeney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marquette</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mayfield Hts.</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taylorville</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Pölten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tromso</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <results_first_submitted>June 30, 2009</results_first_submitted>
  <results_first_submitted_qc>July 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2010</results_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steve Erickson, Principal Clinical Trial Leader</name_title>
    <organization>Medtronic CRDM</organization>
  </responsible_party>
  <keyword>ICD</keyword>
  <keyword>Pacing</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2051 subjects were screened for the study. Of the 2051 subjects screened, 1037 were enrolled in the study. 6 of 1037 subjects later failed to meet other qualifying inclusion criteria and were not randomized and assigned to a study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VVI 40 Pacing</title>
          <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
        </group>
        <group group_id="P2">
          <title>MVP Pacing</title>
          <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="513"/>
                <participants group_id="P2" count="518"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="222"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Heart Transplant/Device Exit/Changeout</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VVI 40 Pacing</title>
          <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
        </group>
        <group group_id="B2">
          <title>MVP Pacing</title>
          <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="513"/>
            <count group_id="B2" value="518"/>
            <count group_id="B3" value="1031"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="11.7"/>
                    <measurement group_id="B2" value="62.6" spread="12.0"/>
                    <measurement group_id="B3" value="62.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="414"/>
                    <measurement group_id="B3" value="819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality and Heart Failure-related Urgent Care Visits and Heart Failure (&quot;HF&quot;) Hospitalizations.</title>
        <description>A composite endpoint of all cause mortality and HF hospitalizations or urgent care. (Emergency Department, Urgent Clinic visits, or hospitalizations wiht intravenous medications for HF)</description>
        <time_frame>Enrollment to last visit (up to 45 months post-randomization) or death</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality and Heart Failure-related Urgent Care Visits and Heart Failure (&quot;HF&quot;) Hospitalizations.</title>
          <description>A composite endpoint of all cause mortality and HF hospitalizations or urgent care. (Emergency Department, Urgent Clinic visits, or hospitalizations wiht intravenous medications for HF)</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a multiple events survival analysis, with time to first primary endpoint, time between successive endpoints, and time from last endpoint to last follow-up visit determined for each subject. The null hypothesis is that the mortality/ heart failure (&quot;HF&quot;) urgent care/HF hospitalization hazard rate for patients with no Class I pacing indication and MVP is greater than that of similar patients with VVI 40.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority analysis was performed, with the hazard ratio as the parameter of interest and the non-inferiority threshold of 1.21. The one-sided upper confidence bound for the hazard ratio had to be less than 1.21 for the null hypothesis to be rejected. The threshold of 1.21 was derived by using a noninferiority threshold of a 5 percentage point difference in 24 month event-free rates.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.139</param_value>
            <ci_percent>96.3</ci_percent>
            <ci_lower_limit>1.139</ci_lower_limit>
            <ci_upper_limit>1.590</ci_upper_limit>
            <estimate_desc>4 interim analyses were performed &amp; the O'Brien-Fleming alpha-spending function required a 96.3% confidence interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Worsening Heart Failure-related Adverse Events</title>
        <description>HF event meeting primary endpoint definition, or adverse events associated with, but not limited to, any of the following: symptoms or physical signs compatible with worsening HF, laboratory evidence of HF, any modification of oral heart failure therapy</description>
        <time_frame>Enrollment to last visit (up to 45 months post-randomization)</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Worsening Heart Failure-related Adverse Events</title>
          <description>HF event meeting primary endpoint definition, or adverse events associated with, but not limited to, any of the following: symptoms or physical signs compatible with worsening HF, laboratory evidence of HF, any modification of oral heart failure therapy</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>participants/events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a multiple events survival analysis, and so the time from randomization to first HF event, time between successive HF events, and time from last HF event to last follow-up visit was determined for each subject. Since non-inferiority analysis is intended to prove that one therapy is equivalent or superior to another therapy, the null hypothesis being tested is that the worsening HF hazard rate for patients with MVP programming is greater than that of patients with VVI 40 programming.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority analysis was performed, with the hazard ratio as the parameter of interest and the non-inferiority threshold of 1.241. The one-sided upper confidence bound for the hazard ratio had to be less than 1.241 for the null hypothesis to be rejected. The threshold of 1.241 was derived by using a non-inferiority threshold of a 5 percentage point difference in 24 month HF event-free rates.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.029</ci_lower_limit>
            <ci_upper_limit>1.381</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of Patients by NYHA (New York Heart Association) Functional Class Over Time</title>
        <description>NYHA Classification at each scheduled Follow-up visit. The scale for this measure is as follows: NYHA I= best, NYHA IV= worst.</description>
        <time_frame>Baseline, 12, 24 and 36 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Patients by NYHA (New York Heart Association) Functional Class Over Time</title>
          <description>NYHA Classification at each scheduled Follow-up visit. The scale for this measure is as follows: NYHA I= best, NYHA IV= worst.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline NYHA Obtained Outside Window</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA Missing due to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month NYHA Missing For Other Reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA Missing due to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month NYHA Missing For Other Reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA Missing due to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month NYHA Missing For Other Reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A model with covariates for time and randomization arm was fit to test the null hypothesis that the risk of worsening NYHA status over time among patients with MVP programming was equal to that of patients with VVI 40 programming. This analysis combined NYHA IV and Death into one category. The model included interaction terms for time and randomization arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <p_value_desc>The a priori alpha level for each covariate was 0.05. The p-value outcome provided is for the randomization arm main effect and all interactions between randomization arm and time.</p_value_desc>
            <method>Cumulative Logits Model</method>
            <method_desc>The analysis included data for all four time points (baseline, 12, 24, and 36 months) and all NYHA levels.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis for this analysis was the same as for the prior analysis: that the risk of worsening NYHA status over time among patients with MVP programming was equal to that of patients with VVI 40 programming. In this analysis, however, death was considered a 5th category in addition to NYHA I-IV. An interaction term for time and randomization arm was also included.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <p_value_desc>The a priori alpha level for each covariate was 0.05. The p-value outcome provided is for the randomization arm main effect and all interaction terms between randomization arm and time.</p_value_desc>
            <method>Cumulative Logit Model</method>
            <method_desc>The analysis included data for all four time points (baseline, 12, 24, and 36 months) and all NYHA levels.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Chamber Dimensions and Wall Thicknesses</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Chamber Dimensions and Wall Thicknesses</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV End Diastolic Dimension(LVEDD) (cm) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="1"/>
                    <measurement group_id="O2" value="6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEDD (cm) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0.9"/>
                    <measurement group_id="O2" value="6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEDD (cm) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1"/>
                    <measurement group_id="O2" value="5.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV End Systolic Dimension (LVESD) (cm) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.1"/>
                    <measurement group_id="O2" value="4.9" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESD (cm) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.1"/>
                    <measurement group_id="O2" value="4.9" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESD (cm) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.1"/>
                    <measurement group_id="O2" value="4.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septal Thickness (cm) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.3"/>
                    <measurement group_id="O2" value="1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septal Thickness (cm) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.3"/>
                    <measurement group_id="O2" value="1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septal Thickness (cm) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.3"/>
                    <measurement group_id="O2" value="1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Wall Thickness (cm) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.2"/>
                    <measurement group_id="O2" value="1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Wall Thickness (cm) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.2"/>
                    <measurement group_id="O2" value="1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Wall Thickness (cm) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.2"/>
                    <measurement group_id="O2" value="1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit for each of the followoing: LVEDD, LVESD, Septal Wall Thickness, and Posterior Wall Thickness; the purpose was to test whether patients with MVP and no pacing indication over time had a different average value for that measure than patients with VVI and no pacing indication. Data were also collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.10</p_value>
            <p_value_desc>In each case the a priori threshold for significance for Arm was 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model fit with time and arm as covariates, the interaction between them included. Interaction shown to not be significant and model refit without it.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular (LV) Ejection Fraction and Fractional Shortening</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Ejection Fraction is the percentage of a patient's blood moved out of the left venricle when the heart pumps. The measure is recorded as a percentage(0-100%) and the normal range is 50-85%.
LV Fractional Shortening is the percent change in a patient's LV internal dimensions between systole (when the ventricles contract and expel blood) and diastole (when the ventricles expand and receive blood). The measure is recorded as a percentage(0-100%) and the normal range is 30-45%.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular (LV) Ejection Fraction and Fractional Shortening</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Ejection Fraction is the percentage of a patient's blood moved out of the left venricle when the heart pumps. The measure is recorded as a percentage(0-100%) and the normal range is 50-85%.
LV Fractional Shortening is the percent change in a patient's LV internal dimensions between systole (when the ventricles contract and expel blood) and diastole (when the ventricles expand and receive blood). The measure is recorded as a percentage(0-100%) and the normal range is 30-45%.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>percentage of LV unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV Fractional Shortening (%) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="9.2"/>
                    <measurement group_id="O2" value="18.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Fractional Shortening (%) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="8.4"/>
                    <measurement group_id="O2" value="20.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Fractional Shortening (%) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="9.1"/>
                    <measurement group_id="O2" value="20.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Ejection Fraction (%) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="11.9"/>
                    <measurement group_id="O2" value="35.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Ejection Fraction (%) at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="11.9"/>
                    <measurement group_id="O2" value="37.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Ejection Fraction (%) at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="12.5"/>
                    <measurement group_id="O2" value="36.7" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit for each of the following: LV Ejection Fraction and LV Fractional Shortening; the purpose was to test whether patients with MVP and no pacing indication over time had a different average value for that measure than patients with VVI and no pacing indication. Two-sided tests were used. Data were also collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.10</p_value>
            <p_value_desc>The a priori threshold for significance for Arm was 0.05, with no adjustment for multiple analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Models were fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular (LV) and Left Atrial (LA) Volumes</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular (LV) and Left Atrial (LA) Volumes</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV End Systolic Volume (LVESV) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.6" spread="65.5"/>
                    <measurement group_id="O2" value="121.2" spread="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.9" spread="59.7"/>
                    <measurement group_id="O2" value="105.8" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESV at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.5" spread="62.6"/>
                    <measurement group_id="O2" value="108.7" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV End Diastolic Volume (LVEDV) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.8" spread="72.7"/>
                    <measurement group_id="O2" value="182.5" spread="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEDV at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.6" spread="68.6"/>
                    <measurement group_id="O2" value="163.2" spread="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEDV at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.0" spread="71.8"/>
                    <measurement group_id="O2" value="165.8" spread="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Atrial (LA) Volume at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="26.1"/>
                    <measurement group_id="O2" value="74.5" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LA Volume at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="28.3"/>
                    <measurement group_id="O2" value="73.6" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LA Volume at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" spread="32.0"/>
                    <measurement group_id="O2" value="77.4" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit to test whether patients with MVP and no pacing indication had a different values for left ventricular end diastolic volume (&quot;LVEDV&quot;) over time than similar patients with VVI 40. A two-sided test was used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0424</p_value>
            <p_value_desc>The a priori threshold for statistical significance for Arm was 0.05, with no correction for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model was fit with time and arm as covariates.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Similar models were fit for left ventricle (&quot;LV&quot;) End Systolic Volume and Left Atrial Volume.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <p_value_desc>In each case the a priori threshold for significance for Arm was 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Models were fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular (LV) Sphericity Index</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Sphericity Index is a ratio of LV long axis dimension to the LV short axis dimension. Healthy hearts have an elliptical LV cross-sectional shape. A value of 1 denotes a circular or more globular shape, while larger values denote healthier hearts with more elliptical cross sections. Literature has shown that when the ratio used is short axis/long axis, normal hearts have a median LV sphericity index of 0.56, with a range of (0.51-0.60). This translates to median=1.79,range=(1.67,1.96) for long/short axis.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular (LV) Sphericity Index</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.
LV Sphericity Index is a ratio of LV long axis dimension to the LV short axis dimension. Healthy hearts have an elliptical LV cross-sectional shape. A value of 1 denotes a circular or more globular shape, while larger values denote healthier hearts with more elliptical cross sections. Literature has shown that when the ratio used is short axis/long axis, normal hearts have a median LV sphericity index of 0.56, with a range of (0.51-0.60). This translates to median=1.79,range=(1.67,1.96) for long/short axis.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Ventricular (LV) Sphericity Index at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Sphericity Index at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV Sphericity Index at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit to test whether patients with MVP and no pacing indication had a different values of Left Ventricular Sphericity Index over time than similar patients with VVI 40. A two-sided test was used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0418</p_value>
            <p_value_desc>The a priori threshold for significance for Arm was 0.05, with no adjustment for multiple analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Velocity Measures</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Velocity Measures</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>meters per second (m/s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tricuspid Regurgitation (TR) Velocity at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.4"/>
                    <measurement group_id="O2" value="2.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TR Velocity at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.4"/>
                    <measurement group_id="O2" value="2.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TR Velocity at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.4"/>
                    <measurement group_id="O2" value="2.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak E at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak E at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak E at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak A at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak A at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - peak A at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit for each of the following: TR Velocity, Mitral Inflow-peak E and Mitral Inflow-peak A; the purpose was to test whether patients with MVP and no pacing indication over time had a different average value for that measure than patients with VVI and no pacing indication. Two-sided tests were used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.10</p_value>
            <p_value_desc>The a priori threshold for statistical significance for Arm was 0.05, with no correction for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Models were fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Deceleration Time</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Deceleration Time</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mitral Inflow - Deceleration Time at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.6" spread="50.6"/>
                    <measurement group_id="O2" value="192.3" spread="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - Deceleration Time at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.8" spread="54.7"/>
                    <measurement group_id="O2" value="208.7" spread="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Inflow - Deceleration Time at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.0" spread="54.6"/>
                    <measurement group_id="O2" value="210.7" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit for Mitral Inflow - Deceleration time; the purpose was to test whether patients with MVP and no pacing indication over time had a different average value for that measure than patients with VVI and no pacing indication. A two-sided test was used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9490</p_value>
            <p_value_desc>The a priori threshold for significance for Arm was 0.05, with no adjustment for multiple analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Atrial (LA) and Mitral Regurgitation (MR) Areas</title>
        <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial (LA) and Mitral Regurgitation (MR) Areas</title>
          <description>Echocardiogram measures for each endpoint were obtained at multiple time points.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>centimeters squared (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Atrial (LA) Area at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="5.8"/>
                    <measurement group_id="O2" value="22.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LA Area at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="5.5"/>
                    <measurement group_id="O2" value="21.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LA Area at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="6.0"/>
                    <measurement group_id="O2" value="21.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mitral Regurgitation (MR) Area at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.3"/>
                    <measurement group_id="O2" value="5.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR Area at 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="4.9"/>
                    <measurement group_id="O2" value="4.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MR Area at 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="4.5"/>
                    <measurement group_id="O2" value="4.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear mixed model was fit for each of the following: Left Atrial Area and Mitral Regurgitation Area; the purpose was to test whether patients with MVP and no pacing indication over time had a different average value for that measure than patients with VVI and no pacing indication. Two-sided tests were used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.10</p_value>
            <p_value_desc>The a priori threshold for significance for Arm was 0.05, with no adjustment for multiple analyses.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Models fit with time and arm as covariates.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Mitral Regurgitation (MR) Severity Score</title>
        <description>Echocardiogram measures for this endpoint were obtained at multiple time points. Composite MR Severity was measured on a scale of &quot;None to Trivial&quot; to &quot;Grade IV&quot;, with Grade IV being the worst possible score and &quot;None to Trivial&quot; being the best possible score.</description>
        <time_frame>Baseline, 12, and 24 month visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Mitral Regurgitation (MR) Severity Score</title>
          <description>Echocardiogram measures for this endpoint were obtained at multiple time points. Composite MR Severity was measured on a scale of &quot;None to Trivial&quot; to &quot;Grade IV&quot;, with Grade IV being the worst possible score and &quot;None to Trivial&quot; being the best possible score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MR Score of None to Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MR Score: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MR Score: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MR Score: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MR Score: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline MR Score: Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month MR Score: None to Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month MR Score: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month MR Score: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month MR Score: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month MR Score: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Score: Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month MR Score: None to Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month MR Score: Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month MR Score: Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month MR Score: Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month MR Score: Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Score: Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A General Estimating Equation (&quot;GEE&quot;) Cumulative Logits model was fit with Arm, Time, and their interaction as covariates in the model to test the hypothesis that patients with no pacing indication and MVP programming have different Mitral Regurgation over time than similar patients with VVI 40 programming. A two-sided test was used. Data were collected from the 36 month visits but were excluded due to the trial being stopped early and only a subset of patients having data for those visits.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8403</p_value>
            <p_value_desc>The a priori threshold for significance for Arm was 0.05.</p_value_desc>
            <method>Cumulative Logits Model</method>
            <method_desc>Because Composite Mitral Regurgitation Score was measured on the ordinal scale, a GEE cumulative logits model was fit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Ventricular Tachycardia (&quot;VT&quot;) and Ventricular Fibrillation (&quot;VF&quot;) Episodes</title>
        <description>Annualized Rates of Days of True VT/VF and Inappropriately detected non-VT/VF</description>
        <time_frame>Enrollment to last collection of data from the implanted ICD (up to 45 months post-randomization)</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Ventricular Tachycardia (&quot;VT&quot;) and Ventricular Fibrillation (&quot;VF&quot;) Episodes</title>
          <description>Annualized Rates of Days of True VT/VF and Inappropriately detected non-VT/VF</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>Annualized Episodes per Patient Month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>True VT/VF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.170"/>
                    <measurement group_id="O2" value="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inappropriately detected non-VT/VF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038"/>
                    <measurement group_id="O2" value="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The pre-specified analysis called for a comparison of the hazard rates of true VT/VF between the two arms by way of a one-sided 95% confidence interval on the hazard ratio (values less than one favor MVP) after fitting a model. The unit of time was days, not episodes, so the analysis did not account for multiple episodes on the same day. If the upper bound was less than 1, the null hypothesis of equal hazard rates would be rejected.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.949</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.949</ci_lower_limit>
            <ci_upper_limit>1.209</ci_upper_limit>
            <estimate_desc>Because of the possible correlation within subject of days with episodes, a subsequent analysis was done using a bootstrap confidence interval for the annualized rate of episodes per patient month.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A 95% one-sided bootstrap confidence interval was generated for the MVP - VVI 40 difference in annualized rates of true VT/VF per patient month. If the interval upper bound was less than 0, the null hypothesis of equal rates would be rejected.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Annualized Rates</param_type>
            <param_value>-0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The pre-specified analysis called for a comparison of the hazard rates of inappropriately detected non-VT/VF between the two arms by way of a one-sided 95% confidence interval on the hazard ratio (MVP in numerator) after fitting a model. The unit of time was days, not episodes, so the analysis did not account for multiple episodes on the same day. If the upper bound was less than 1, the null hypothesis of equal hazard rates would be rejected.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.310</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.310</ci_lower_limit>
            <ci_upper_limit>1.858</ci_upper_limit>
            <estimate_desc>Because of the possible correlation within a subject for days with episodes, a subsequent analysis was done using a bootstrap confidence interval for the annualized rate of episodes per patient month.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A 95% one-sided bootstrap confidence interval was generated for the MVP - VVI 40 difference in annualized rates of inappropriately detected non-VT/VF per patient month. If the interval upper bound was less than 0, the null hypothesis of equal rates would be rejected.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Annualized Rates</param_type>
            <param_value>0.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.036</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Clinically Important or Persistent Atrial Tachycardia or Atrial Fibrillation (AT/AF) in Subjects With no Prior AF History</title>
        <description>Persistent AF was defined as any of the following:
2 consecutive visits in which the patient presents with AF
7 consecutive days of at least 22 hours per day of AT/AF
A cardioversion prior to 7 consecutive days of at least 22 hours per day of AT/AF
Clinically Important AF was defined as more than 20 hours of AT/AF in a single day</description>
        <time_frame>Enrollment to last collection of data from the implanted ICD (up to 45 months post-randomization)</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic AF, which was an exclusion criterion. Of the remaining 1030 randomized subjects that met all inclusion criteria, only those with no history of AF were included in the analysis (445 in the VVI 40 arm and 444 in the MVP arm). An intention to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Clinically Important or Persistent Atrial Tachycardia or Atrial Fibrillation (AT/AF) in Subjects With no Prior AF History</title>
          <description>Persistent AF was defined as any of the following:
2 consecutive visits in which the patient presents with AF
7 consecutive days of at least 22 hours per day of AT/AF
A cardioversion prior to 7 consecutive days of at least 22 hours per day of AT/AF
Clinically Important AF was defined as more than 20 hours of AT/AF in a single day</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic AF, which was an exclusion criterion. Of the remaining 1030 randomized subjects that met all inclusion criteria, only those with no history of AF were included in the analysis (445 in the VVI 40 arm and 444 in the MVP arm). An intention to treat analysis was performed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compared the hazard rates for clinically important AF (defined as a calendar day with &gt;20 hour of AT/AF as measured by the device). The null hypothesis was that this hazard rate for patients with MVP was equal to or greater than that of patients with VVI 40. The pre-specified model had Arm as a covariate, and accounted for time to first event and time between successive events per subject.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7166</p_value>
            <p_value_desc>The threshold for significance was the one-sided upper confidence bound being less than 1.</p_value_desc>
            <method>Andersen-Gill model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compared the percentage of days with &gt;20 hours of AT/AF as measured by the device(definition of clinically important AF) between arms. The null hypothesis was that this percentage of days for patients with MVP was equal or greater to that of patients with VVI 40.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-100</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis tested the null hypothesis that the hazard rate for development of persistent AF(defined as 2 consecutive visits presenting with AT/AF, 7 consecutive days of 22 or more hours per day of AT/AF, or &lt; 7 such days due to a cardioversion) in patients with MVP and no pacing indication was equal to or greater than that of similar patients with VVI 40.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>A one-sided test was used.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis tested the hypothesis that the average AT/AF burden (hours per day of AT/AF) through 6 months post-implant in patients with no Class I pacing indication and MVP is equal to or greater than that of similar patients with VVI 40. Only subjects with complete AT/AF data for this time interval were included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis tested the hypothesis that the average AT/AF burden (hours per day of AT/AF) from 6 to 12 months post-implant in patients with no Class I pacing indication and MVP is equal to or greater than that of similar patients with VVI 40. Only subjects with complete AT/AF data for this time interval were included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.227</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis tested the hypothesis that the average AT/AF burden (hours per day of AT/AF) from 12 to 24 months post-implant in patients with no Class I pacing indication and MVP is equal to or greater than that of similar patients with VVI 40. Only subjects with complete AT/AF data for this time interval were included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis tested the hypothesis that the average AT/AF burden (hours per day of AT/AF) from 24 to 36 months post-implant in patients with no Class I pacing indication and MVP is equal to or greater than that of similar patients with VVI 40. Only subjects with complete AT/AF data for this time interval were included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of a Pacing Indication During the Study</title>
        <description>Physician identification of a Class I Pacing Indication. A Class I Pacing Indication implies that the benefit of pacing the heart far exceeds the risk, and that the procedure to implant the pacing device should be performed. For this indication there is general agreement that pacing the heart is beneficial, useful, and effective.</description>
        <time_frame>Enrollment to last visit (up to 45 months post-randomization)</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Development of a Pacing Indication During the Study</title>
          <description>Physician identification of a Class I Pacing Indication. A Class I Pacing Indication implies that the benefit of pacing the heart far exceeds the risk, and that the procedure to implant the pacing device should be performed. For this indication there is general agreement that pacing the heart is beneficial, useful, and effective.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physicians recorded at each scheduled and unscheduled follow-up whether the subject had developed a Class I indication since their last visit. The time from randomization to Class I indication development or last visit if censored was determined for each subject. The null hypothesis was that the hazard rate for time to development of a Class I pacing indication among patients with MVP programming was equal to or greater than that of patients with VVI 40 programming.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05. The threshold was met, and the null hypothesis rejected.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Usage Affecting Heart Rate and Atrioventricular (&quot;AV&quot;) Conduction</title>
        <description>Whether a subject is on each of a pre-specified set of drugs or classes of drugs.</description>
        <time_frame>Enrollment, 6 Months, 12 Months, 24 Months, 30 Months, 36 Months</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Usage Affecting Heart Rate and Atrioventricular (&quot;AV&quot;) Conduction</title>
          <description>Whether a subject is on each of a pre-specified set of drugs or classes of drugs.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Amiodarone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Sotalol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7"/>
                    <measurement group_id="O2" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1"/>
                    <measurement group_id="O2" value="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.0"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Beta Blockers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3"/>
                    <measurement group_id="O2" value="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Amlodipine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Diltiazem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Verapamil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9"/>
                    <measurement group_id="O2" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6"/>
                    <measurement group_id="O2" value="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0"/>
                    <measurement group_id="O2" value="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month ACE-Inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7"/>
                    <measurement group_id="O2" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month ARBs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Aldosterone Receptor Antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Spironolactone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2"/>
                    <measurement group_id="O2" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                    <measurement group_id="O2" value="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Diuretics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Month Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Month Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Month Digoxin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Ventricular Pacing</title>
        <description>The percentage of a patients' ventricular beats that were paced by the device.</description>
        <time_frame>Enrollment, 6, 12, 24 and 36 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Ventricular Pacing</title>
          <description>The percentage of a patients' ventricular beats that were paced by the device.</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>Percent pacing</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.7"/>
                    <measurement group_id="O2" value="0.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="5.5"/>
                    <measurement group_id="O2" value="1.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="8.0"/>
                    <measurement group_id="O2" value="1.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to 36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="13.8"/>
                    <measurement group_id="O2" value="1.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All subjects from the analysis cohort with available data for the time period of interest were included in the corresponding analysis. The null hypothesis was that the average percent ventricular pacing through 6 months post-implant for patients with MVP programming and was greater than or equal to that of patients with VVI 40 programming.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9791</p_value>
            <p_value_desc>The one-sided Wilcoxon Rank Sum test yielded a p-value greater than 0.05, which was the a priori threshold for significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All subjects from the analysis cohort with available data for the time period of interest were included in the corresponding analysis. The null hypothesis was that the average percent ventricular pacing through 12 months post-implant for patients with MVP programming was greater than or equal to that of patients with VVI 40 programming.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8984</p_value>
            <p_value_desc>The one-sided Wilcoxon Rank Sum test yielded a p-value greater than 0.05, which was the a priori threshold for significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Alternative hypothesis:patients with MVP &amp; no pacing indication have less mean ventricular pacing through 12 months than similar patients with VVI 40.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All subjects from the analysis cohort with available data for the time period of interest were included in the corresponding analysis. The null hypothesis was that the average percent ventricular pacing through 24 months post-implant for patients with MVP programming and no pacing indication was greater than or equal to that of patients with VVI 40 programming and no pacing indication.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7144</p_value>
            <p_value_desc>The one-sided Wilcoxon Rank Sum test yielded a p-value greater than 0.05, which was the a priori threshold for significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Alternative hypothesis:patients with MVP &amp; no pacing indication have less mean ventricular pacing through 24 months than similar patients with VVI 40.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>All subjects from the analysis cohort with available data for the time period of interest were included in the corresponding analysis. The null hypothesis was that the average percent ventricular pacing through 36 months post-implant for patients with MVP programming and no pacing indication was greater than or equal to that of patients with VVI 40 programming and no pacing indication.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5165</p_value>
            <p_value_desc>The one-sided Wilcoxon Rank Sum test yielded a p-value greater than 0.05, which was the a priori threshold for significance.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Alternative hypothesis:patients with MVP &amp; no pacing indication have less mean ventricular pacing through 36 months than similar patients with VVI 40.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (&quot;QOL&quot;) Score</title>
        <description>Minnesota Living with Heart Failure Questionnaire (&quot;MLWHFQ&quot;) and Kansas City Cardiomyopathy Questionnaire (&quot;KCCQ&quot;) Quality of Life(&quot;QOL&quot;) Scores. For KCCQ, positive values mean improved QOL compared to baseline. For MLWHFQ, negative values mean improved QOL compared to baseline.
Scales: KCCQ 0-100 (0=worst, 100 best); MLWHFQ 0-105 (105=worst, 0=best)</description>
        <time_frame>Baseline, 12, 24, and 36 month visits</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (&quot;QOL&quot;) Score</title>
          <description>Minnesota Living with Heart Failure Questionnaire (&quot;MLWHFQ&quot;) and Kansas City Cardiomyopathy Questionnaire (&quot;KCCQ&quot;) Quality of Life(&quot;QOL&quot;) Scores. For KCCQ, positive values mean improved QOL compared to baseline. For MLWHFQ, negative values mean improved QOL compared to baseline.
Scales: KCCQ 0-100 (0=worst, 100 best); MLWHFQ 0-105 (105=worst, 0=best)</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KCCQ Physical Limitation(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="25.8"/>
                    <measurement group_id="O2" value="4.1" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Physical Limitation(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="28.5"/>
                    <measurement group_id="O2" value="-0.1" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Physical Limitation(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="32.5"/>
                    <measurement group_id="O2" value="-11.0" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Stability(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="28.5"/>
                    <measurement group_id="O2" value="3.1" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Stability(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="28.5"/>
                    <measurement group_id="O2" value="-0.6" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Stability(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="29.0"/>
                    <measurement group_id="O2" value="-10.5" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Frequency(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="27.8"/>
                    <measurement group_id="O2" value="5.1" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Frequency(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="31.9"/>
                    <measurement group_id="O2" value="1.7" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Frequency(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="37.4"/>
                    <measurement group_id="O2" value="-10.1" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Burden(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="27.7"/>
                    <measurement group_id="O2" value="5.9" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Burden(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="32.3"/>
                    <measurement group_id="O2" value="3.2" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Symptom Burden(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="38.2"/>
                    <measurement group_id="O2" value="-8.6" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Total Symptoms(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="26.7"/>
                    <measurement group_id="O2" value="5.5" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Total Symptoms(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="31.2"/>
                    <measurement group_id="O2" value="2.4" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Total Symptoms(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" spread="36.9"/>
                    <measurement group_id="O2" value="-9.3" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Self-Efficacy(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="28.9"/>
                    <measurement group_id="O2" value="4.9" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Self-Efficacy(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="34.1"/>
                    <measurement group_id="O2" value="-0.2" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Self-Efficacy(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="43.2"/>
                    <measurement group_id="O2" value="-12.5" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Quality of Life(12 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="31.8"/>
                    <measurement group_id="O2" value="16.6" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Quality of Life(24 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="35.7"/>
                    <measurement group_id="O2" value="14.6" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Quality of Life(36 Mo. -Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="39.4"/>
                    <measurement group_id="O2" value="0.9" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Social Limitation(12 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="31.7"/>
                    <measurement group_id="O2" value="8.1" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Social Limitation(24 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="35.9"/>
                    <measurement group_id="O2" value="6.1" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Social Limitation(36 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="40.7"/>
                    <measurement group_id="O2" value="-2.3" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary(12 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="25.1"/>
                    <measurement group_id="O2" value="8.7" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary(24 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="29.4"/>
                    <measurement group_id="O2" value="5.7" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Overall Summary(36 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="34.7"/>
                    <measurement group_id="O2" value="-5.4" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary(12 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="24.1"/>
                    <measurement group_id="O2" value="4.9" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary(24 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="28.1"/>
                    <measurement group_id="O2" value="1.2" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KCCQ Clinical Summary(36 Mo.-Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="33.8"/>
                    <measurement group_id="O2" value="-9.7" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLWHFQ (12 Month - Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="24.6"/>
                    <measurement group_id="O2" value="-7.9" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLWHFQ (24 Month - Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="30.6"/>
                    <measurement group_id="O2" value="-4" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MLWHFQ (36 Month - Baseline Change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="37"/>
                    <measurement group_id="O2" value="5.9" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Physical Limitation Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Symptom Stability Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2493</p_value>
            <p_value_desc>No adjustment was made for multiple comparisons, and the a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Symptom Frequency Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7728</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Symptom Burden Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3082</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Total Symptom Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5422</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Self-Efficacy Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0851</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Quality of Life Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0502</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Social Limitation Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0463</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Overall Summary Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0227</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the KCCQ Overall Clinical Summary Score, the change from baseline to 12 months was compared between the two arms, using a two-sided test. If a subject died prior to the time point, a score of 0 was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0582</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 10 KCCQ analyses were repeated comparing changes from baseline to 24 months between arms. Again if a subject died prior to their 24 month visit, a value of 0 was imputed for their 24 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.15</p_value>
            <p_value_desc>Tests for all ten KCCQ subscores yielded p-values greater than 0.15 (the a priori threshold for statistical significance was 0.05).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 10 KCCQ analyses were repeated comparing changes from baseline to 36 months between arms. Again if a subject died prior to their 36 month visit, a value of 0 was imputed for their 36 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.15</p_value>
            <p_value_desc>Tests for all 10 KCCQ subscores yielded p-values greater than 0.15 (the a priori threshold for statistical significance was 0.05).</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Because the trial was stopped early, only 178 subjects were included in these analyses.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in Minnesota Living with Heart Failure Questionnaire score from baseline to 12 months was compared using a two-sided test. If a subject died before their 12 month visit, a value of 105 (worst possible MLWHF score) was imputed for their 12 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1399</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in Minnesota Living with Heart Failure Questionnaire score from baseline to 24 months was compared using a two-sided test. If a subject died before their 24 month visit, a value of 105 (worst possible MLWHF score) was imputed for their 24 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3573</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, and no adjustment was made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in Minnesota Living with Heart Failure Questionnaire score from baseline to 36 months was compared using a two-sided test. If a subject died before their 36 month visit, a value of 105 (worst possible MLWHF score) was imputed for their 36 month score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5183</p_value>
            <p_value_desc>The a priori threshold for statistical significance was 0.05, with no adjustment made for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Because the trial was stopped early, only 178 subjects were included in this analysis.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <description>Death from any cause</description>
        <time_frame>Enrollment to last visit (up to 45 months post-randomization) or death</time_frame>
        <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>VVI 40</title>
            <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
          </group>
          <group group_id="O2">
            <title>MVP Pacing</title>
            <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Death from any cause</description>
          <population>1 of 1031 randomized subjects had a history of at least 6 months of chronic atrial fibrillation (&quot;AF&quot;), which was an exclusion criterion. The remaining 1030 randomized subjects met all inclusion criteria and made up the analysis cohort. An intention to treat analysis was performed for this objective.</population>
          <units>participants who died</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="512"/>
                <count group_id="O2" value="518"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The time from randomization to all cause mortality or last follow-up visit was determined for each subject. The null hypothesis was that the mortality hazard rate for patients with MVP programming was greater than that of patients with VVI40 programming.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A non-inferiority analysis was performed, with the hazard ratio as the parameter of interest and the non-inferiority threshold of 1.44. The one-sided upper confidence bound for the hazard ratio had to be less than 1.44 for the null hypothesis to be rejected. The threshold of 1.44 was derived by using a noninferiority threshold of a 5 percentage point difference in 24 month survival rates.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>This was a non-inferiority analysis, and so a one-sided 95% confidence interval was performed comparing the MVP arm to the VVI 40 arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICD-indicated Patients With Class I Pacemaker Indication.</title>
        <description>Number of subjects screened prior to enrollment that had Class I pacing indication at time of implant</description>
        <time_frame>Period of time prior to patient consent when considering patient for Implant/Enrollment</time_frame>
        <population>Centers kept a screening log, recording for each patient considered for new ICD implant and possible trial enrollment whether the patient had a Class I pacing indication at time of implant. The analysis consisted of descriptive statistics (counts of the 2051 screened patients).</population>
        <group_list>
          <group group_id="O1">
            <title>All Screened Patients</title>
            <description>All Patients Screened for Possible Enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>ICD-indicated Patients With Class I Pacemaker Indication.</title>
          <description>Number of subjects screened prior to enrollment that had Class I pacing indication at time of implant</description>
          <population>Centers kept a screening log, recording for each patient considered for new ICD implant and possible trial enrollment whether the patient had a Class I pacing indication at time of implant. The analysis consisted of descriptive statistics (counts of the 2051 screened patients).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2051"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Class I Pacing Indication at Implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Class I Pacing Indication at Implant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1818" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class I Pacing Indication Status Not Recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to study exit or closure (up to 45 months post-randomization)</time_frame>
      <desc>Adverse Events defined as any undesirable clinical occurrence in a subject. Data collection limited to cardiovascular, pulmonary or renal system (including system and procedure-related events) or events in which the subject presented with symptoms compatible with fluid retention and/or decreased exercise tolerance.</desc>
      <group_list>
        <group group_id="E1">
          <title>VVI 40 Pacing</title>
          <description>Backup ventricular pacing at a rate of 40 beats per minute</description>
        </group>
        <group group_id="E2">
          <title>MVP Pacing</title>
          <description>Managed Ventricular Pacing at a rate of 60 beats per minute</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pantocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="513"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="91" subjects_affected="50" subjects_at_risk="513"/>
                <counts group_id="E2" events="88" subjects_affected="53" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="513"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction with Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="513"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia and Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Cerebellar Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Cerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disorder with Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Cellulitis and Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Coronary Artery Disease and Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Coronary Artery Disease, SVT and VT</sub_title>
                <description>Congestive Heart Failure with Coronary Artery Disease, Supraventricular Tachycardia (SVT) and Ventricular Tachycardia (VT)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Infection - Respiratory Tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Myocardial Infarction and Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Pneumonia and Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Pneumothorax and Right Atrial Lead Dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure with Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease with Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Increased Right Ventricular Lead Impedance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Lead Dislodgement - Right Ventricular Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Lead Fracture - Right Ventricular Lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Lead Perforation - Right Ventricular Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Lead Protrusion - Right Ventricular Lead</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Medication Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pleural Effusion with Renal Failure and Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pneumonia with Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Premature Battery Depletion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Respiratory Failure with Pneumonia and Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="513"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="513"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Subdural Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Infection - Device, Leads</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Infection - Incision Site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Infection - Pocket</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Infection - Systemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Infection - Urinary Tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Closed Head Trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Leukemia - Myelogenous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="513"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="513"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Sleep Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Necrosis - Left Lower Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="513"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="513"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="513"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="42" subjects_affected="36" subjects_at_risk="513"/>
                <counts group_id="E2" events="51" subjects_affected="43" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="73" subjects_affected="55" subjects_at_risk="513"/>
                <counts group_id="E2" events="59" subjects_affected="44" subjects_at_risk="518"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="513"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="518"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In most cases, contracts allow investigators (&quot;PI&quot;) to publish per the publication strategy/Clinical Investigational Plan following Medtronic's review for (a) disclosure of confidential information (&quot;CI&quot;), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MVP Clinical Trial Leader</name_or_title>
      <organization>Medtronic, Inc.</organization>
      <email>medtroniccrmtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

